Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
Monoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hy...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/8/1861 |
| _version_ | 1797411127120887808 |
|---|---|
| author | Pardis Mokhtary Zeinab Pourhashem Akram Abouei Mehrizi Claudia Sala Rino Rappuoli |
| author_facet | Pardis Mokhtary Zeinab Pourhashem Akram Abouei Mehrizi Claudia Sala Rino Rappuoli |
| author_sort | Pardis Mokhtary |
| collection | DOAJ |
| description | Monoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hybridoma technique introduced in 1975 or by means of modern technologies. Additional methods have been developed to generate mAbs with new biological properties such as humanized, chimeric, or murine. The inclusion of mAbs in therapeutic regimens is a major medical advance and will hopefully lead to significant improvements in infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and Drug Administration (FDA) in 1986, the list of approved mAbs and their clinical indications and applications have been proliferating. New technologies have been developed to modify the structure of mAbs, thereby increasing efficacy and improving delivery routes. Gene delivery technologies, such as non-viral synthetic plasmid DNA and messenger RNA vectors (DMabs or mRNA-encoded mAbs), built to express tailored mAb genes, might help overcome some of the challenges of mAb therapy, including production restrictions, cold-chain storage, transportation requirements, and expensive manufacturing and distribution processes. This paper reviews some of the recent developments in mAb discovery against viral infections and illustrates how mAbs can help to combat viral diseases and outbreaks. |
| first_indexed | 2024-03-09T04:40:31Z |
| format | Article |
| id | doaj.art-eb77afc45338451382b45bc0de320d38 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T04:40:31Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-eb77afc45338451382b45bc0de320d382023-12-03T13:21:36ZengMDPI AGBiomedicines2227-90592022-08-01108186110.3390/biomedicines10081861Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral InfectionsPardis Mokhtary0Zeinab Pourhashem1Akram Abouei Mehrizi2Claudia Sala3Rino Rappuoli4Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, 53100 Siena, ItalyStudent Research Committee, Pasteur Institute of Iran, Tehran 1316943551, IranMalaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, IranMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, 53100 Siena, ItalyMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, 53100 Siena, ItalyMonoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hybridoma technique introduced in 1975 or by means of modern technologies. Additional methods have been developed to generate mAbs with new biological properties such as humanized, chimeric, or murine. The inclusion of mAbs in therapeutic regimens is a major medical advance and will hopefully lead to significant improvements in infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and Drug Administration (FDA) in 1986, the list of approved mAbs and their clinical indications and applications have been proliferating. New technologies have been developed to modify the structure of mAbs, thereby increasing efficacy and improving delivery routes. Gene delivery technologies, such as non-viral synthetic plasmid DNA and messenger RNA vectors (DMabs or mRNA-encoded mAbs), built to express tailored mAb genes, might help overcome some of the challenges of mAb therapy, including production restrictions, cold-chain storage, transportation requirements, and expensive manufacturing and distribution processes. This paper reviews some of the recent developments in mAb discovery against viral infections and illustrates how mAbs can help to combat viral diseases and outbreaks.https://www.mdpi.com/2227-9059/10/8/1861monoclonal antibodymAbviral infections |
| spellingShingle | Pardis Mokhtary Zeinab Pourhashem Akram Abouei Mehrizi Claudia Sala Rino Rappuoli Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections Biomedicines monoclonal antibody mAb viral infections |
| title | Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections |
| title_full | Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections |
| title_fullStr | Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections |
| title_full_unstemmed | Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections |
| title_short | Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections |
| title_sort | recent progress in the discovery and development of monoclonal antibodies against viral infections |
| topic | monoclonal antibody mAb viral infections |
| url | https://www.mdpi.com/2227-9059/10/8/1861 |
| work_keys_str_mv | AT pardismokhtary recentprogressinthediscoveryanddevelopmentofmonoclonalantibodiesagainstviralinfections AT zeinabpourhashem recentprogressinthediscoveryanddevelopmentofmonoclonalantibodiesagainstviralinfections AT akramaboueimehrizi recentprogressinthediscoveryanddevelopmentofmonoclonalantibodiesagainstviralinfections AT claudiasala recentprogressinthediscoveryanddevelopmentofmonoclonalantibodiesagainstviralinfections AT rinorappuoli recentprogressinthediscoveryanddevelopmentofmonoclonalantibodiesagainstviralinfections |